Exploration of the influence of GOLGA8B on prostate cancer progression and resistance of castration-resistant prostate cancer to cabazitaxel

Abstract

Castration-resistant prostate cancer (CRPC) is the final stage of prostate cancer (PCa). Cabazitaxel is a taxane chemotherapy drug used in treating CRPC. However, patients with CRPC will eventually develop resistance to cabazitaxel, but the mechanism remains unclear. Here, we aimed to investigate potential genetic alterations that may play a role in CRPC resistance to cabazitaxel. Using RNA-sequence data from GSE158494 dataset, we identified ten critical genes (CXCL8, ITGB8, CLIP4, MAP1B, WIPI1, MMP13, CXCL1, C1S, GOLGA8B, CXCL6) associated with CRPC cell resistance to cabazitaxel. The potential function of these key genes in PCa progression was analyzed using different databases such as Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), and Chinese Prostate Cancer Genome and Epigenome Atlas (CPGEA). We found that these genes showed altered expression upon the occurrence of PCa and CRPC. Furthermore, CXCL1and GOLGA8B were found to affect the disease-free survival (DFS) status of patients with PCa. GOLGA8B was also found to affect prognosis in patients with PCa. Additionally, GOLGA8B expression was associated with many types of immune cells infiltration in PCa and was upregulated in clinical PCa and CRPC samples. Using CCK-8 assays, we found that GOLGA8B could also influence the sensitivity of CRPC cells to cabazitaxel and docetaxel. In conclusion, we found that GOLGA8B is an important gene that influences PCa progression and CRPC resistance to cabazitaxel.